IGC Pharma, Inc. (IGC)

[NYOptionsGuy]

SeeThruEquity Issues $1.20 Price Target on India Globalization Capital

New York, NY - Oct. 20, 2017 --/ D.M.O. Newswire /-- SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update note on India Globalization Capital, Inc. (NYSE:IGC).

The report is available here: IGC Update Note.

India Globalization Capital, Inc. ("IGC") develops cannabis-based combination therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. In India, the Company is engaged in heavy equipment rental, and in Malaysia, real-estate management. IGC's registered US office is located in Bethesda, Maryland. The company maintains an R&D center in Washington state, and also has a back office in Kochi, Kerala India.

Rest of article and source: https://www.dailymarijuanaobserver.com/single-post/2017/10/20/IGC-SeeThruEquity-Issues-120-Price-Target-on-India-Globalization-Capital